HCW Biologics Business Summary

HCW Biologics Inc. (HCWB) is a clinical-stage biopharmaceutical firm that monetizes its proprietary TOBI™ (Tissue factor-based fusion) and TRBC (T-cell receptor β chain constant region) platforms through a hybrid model of internal development and external licensing. Revenue is primarily generated via upfront fees, milestone payments, and R&D cost-sharing, exemplified by the February 2026 closing of a $7.0 million joint venture agreement with WY Biotech to form Trimmune for the advancement of HCW11-006. The company’s pipeline is bifurcated into oncology—targeting chemotherapy-refractory solid tumors with lead candidate HCW9218—and age-related inflammatory diseases, focusing on regulatory T-cell activation via HCW9302. HCW Biologics competes directly with Unity Biotechnology, ImmunityBio, and Hoth Therapeutics, distinguishing itself by targeting "inflammaging" through multi-functional biologics that neutralize pro-inflammatory cytokines while simultaneously stimulating effector immune cells. The company was founded by Dr. Hing C. Wong, who serves as Chairman and CEO, bringing a distinguished pedigree as the former founder of Altor BioScience, where he developed the IL-15 complex now central to ImmunityBio’s portfolio. The executive suite is further comprised of CFO Rebecca Byam, a specialist in life sciences financial management, and CSO Dr. Peter Rhode, who manages the transition of the company’s fusion protein candidates into late-stage clinical trials. Governance is provided by a seasoned board including Independent Chairman Scott T. Garrett and directors Rick S. Greene and Lisa M. Giles. Beyond its public shareholders, HCW Biologics leverages strategic relationships with ImmunityBio and has recently attracted capital from tier-one Chinese venture partners, including CITIC Medical Fund and TigerYeah Capital, to accelerate its global clinical development programs.